Events & Presentations

A novel cardiotropic AAV variant 4D-C102 demonstrates: superior gene delivery and reduced immunogenicity in cardiac tissues versus wildtype AAV in non-human primates, and results in functional GLA in cardiomyocytes and Fabry fibroblasts

Kevin Whittlesey, Gabriel Brooks, Roxanne Croze, Chris Schmitt, Paul Szymanski, Julie Nye, Melissa Quezada, Ghezal Beliakoff, David Schaffer, Peter Francis, Melissa Kotterman, David Kirn. Poster presented at the 6th Update on Fabry Disease conference, May 26-28, 2019, Prague, Czech ...

4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia

Emeryville, CA – November 16, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that the U.S. Food and Drug Administration (FDA) has ...

4D Molecular Therapeutics to Participate at Upcoming Investor Conferences

Emeryville, CA – November 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor ...